Recombinant Human Endostatin Market
完整報告名稱與涵蓋範圍
Recombinant Human Endostatin Market Size, Share & Trends Analysis Report By Type (purity 95% and others) And By Application (medical care, scientific research and others), By Region, And By Segment Forecasts, 2024-2031.
報告摘要
The worldwide Recombinant Human Endostatin Market stood at USD 133.3 Mn in 2023, and is projected to reach USD 249.4 Mn by 2031, recording a CAGR of 8.3% from 2024 through 2031.
At its core, Recombinant Human Endostatin pertains to a naturally occurring protein in the human body that prevents angiogenesrepresents and has been bioengineered. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
Market momentum is propelled by rising interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, propelled by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Recombinant Human Endostatin Market Snapshot
Chapter 4. Global Recombinant Human Endostatin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Purity 95%
5.2.2. Others
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Medical Care
6.2.2. Scientific Research
6.2.3. Others
Chapter 7. Recombinant Human Endostatin Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.1.2. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.1.3. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.2. Europe
7.2.1. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.2.2. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.2.3. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.3.2. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.3.3. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.4. Latin America
7.4.1. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.4.2. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.4.3. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.5.2. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.5.3. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Pfizer Inc.
8.2.2. Novus Biologicals
8.2.3. Biocon
8.2.4. Thermo Fisher Scientific
8.2.5. Yantai Medgenn Ltd.
8.2.6. FUJIFILM KYOWA KIRIN BIOLOGICS Co. Ltd.
8.2.7. PeproTech, Inc.
8.2.8. Onyx Pharmaceuticals, Inc.
8.2.9. Genexine, Inc.
8.2.10. Hetero.
8.2.11. Intas Pharmaceuticals Ltd.
8.2.12. Novartis AG.
8.2.13. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們